Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
July 24, 2026BiologyOpen Access

Circulating Tumor DNA in Multiple Myeloma: Current Insights and Future Perspectives

View Full Paper
Ask AI
Bookmark
Share

Authors

ASAleksandra SretenovicMMM. MitrovicNVNikola Vukosavljevic

Discussion

Loading...

Member takes

Overview

Review outlines ctDNA as a biomarker for disease assessment and monitoring in multiple myeloma, suggesting significant clinical implications.

Key Points

  • This research highlights the role of circulating tumor DNA (ctDNA) as a promising biomarker in multiple myeloma for disease assessment and monitoring.
  • Review of recent advancements in ctDNA detection techniques, including digital droplet polymerase chain reaction and next-generation sequencing.
  • Assessment of ctDNA's concordance with bone marrow genomic profiles and its utility in monitoring disease dynamics.
  • Discussion on challenges in clinical implementation due to low ctDNA concentrations and methodological standardization.
  • ctDNA analysis provides a dynamic insight into tumor burden and clonal evolution, with substantial concordance to bone marrow profiles.
  • ctDNA successfully identifies resistant subclones and genomic evolution during therapy.
  • Despite the potential benefits, practical limitations hinder routine use in clinical settings.

Cite This Study

Sretenovic et al. (2026) studied this question.

synapsesocial.com/papers/6a63011f395161722cd15cb1https://doi.org/10.3390/biology15141208
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Liquid biopsy for non-invasive molecular characterization and measurable residual disease analysis in multiple myeloma2025
  2. 2Pilot study of cell-free DNA (cfDNA) for measurable residual disease monitoring following autologous hematopoietic cell transplant in multiple myeloma2025 · 2 citations
  3. 3Analysis of cell-free DNA in lymphomas: from sample collection to genotyping and minimal residual disease monitoring2026
  4. 4Novel method of minimal residual disease testing in myeloma: Liquid biopsies to enumerate and 3D telomere-profiling of circulating tumor cells2025 · 1 citations
  5. 5Liquid biopsy for minimal residual disease and monitoring in early-stage non-small cell lung cancer: current clinical utility and implementation challenges2025 · 1 citations